Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised SBB in connection with a directed share issue
Mandate

Vinge has advised SBB in connection with a directed share issue

November 24, 2021 Capital Markets and Public M&A

Vinge has advised Samhällsbyggnadsbolaget i Norden AB (”SBB”) in connection with a directed share issue, whereby SBB receives proceeds of approximately MSEK 500.


The subscription price amounts to SEK 70 per Class B common share, which corresponds to a premium of approximately 3.95 percent compared with the closing price for the Class B common share prior to the issue. The new share issue was directed to Gösta Welandson with related parties as well as Wallenstam AB.

Vinge’s team consisted of Jesper Schönbeck, Rikard Lindahl, Joel Magnusson and Anna Svensson.

Related

Vinge advises OsteoCentric on the public offer for Integrum

 OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

 Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

 Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025